Ioflupane I-123 (DB08824): A Comprehensive Monograph on a Radiopharmaceutical Agent for Neurodegenerative Disease Imaging

Executive Summary

Ioflupane I-123 is a small-molecule radiopharmaceutical agent that has become an indispensable tool in the field of nuclear neurology for the diagnostic evaluation of neurodegenerative disorders. It is specifically designed for the visualization of striatal dopamine transporters (DATs) using Single Photon Emission Computed Tomography (SPECT) brain imaging.[1] The core mechanism of action of Ioflupane I-123 relies on its high binding affinity for presynaptic DATs, which are transmembrane proteins integral to the regulation of synaptic dopamine. By carrying the gamma-emitting radionuclide Iodine-123 to these transporters, the agent allows for the in-vivo quantification and spatial mapping of dopaminergic neuron integrity within the brain's nigrostriatal pathway.[3] A reduction in the density of these transporters serves as a robust biomarker for the neuronal loss characteristic of certain neurodegenerative conditions.

The primary clinical indications for Ioflupane I-123 SPECT imaging are centered on its ability to aid in complex differential diagnoses. Its foundational use is in the evaluation of adult patients with suspected Parkinsonian Syndromes (PS), where it helps to distinguish tremor caused by conditions with presynaptic dopaminergic deficits (e.g., Idiopathic Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy) from Essential Tremor, a condition in which the dopaminergic system remains intact.[1] More recently, its indication has been expanded to assist in the differentiation of Dementia with Lewy Bodies (DLB) from Alzheimer's Disease (AD), a distinction with profound implications for patient management and safety.[6]

Clinical efficacy has been robustly established through a series of pivotal trials, which demonstrated high sensitivity and specificity for the detection of striatal dopaminergic deficits when compared against a reference standard of long-term expert clinical diagnosis.[8] The safety profile of Ioflupane I-123 is generally favorable, with most reported adverse reactions being mild, transient, and infrequent, such as headache, nausea, and vertigo.[1] However, two critical safety considerations mandate strict adherence to protocol: the potential for hypersensitivity reactions and the mandatory administration of a thyroid-blocking agent prior to injection. This latter precaution is essential to prevent the uptake of free radioiodide by the thyroid gland, thereby mitigating the long-term risk of neoplasia.[1]

In clinical practice, Ioflupane I-123 has significantly enhanced diagnostic accuracy, particularly in cases where clinical presentation is ambiguous or atypical. By providing objective biological evidence of the state of the dopaminergic system, it serves as a powerful adjunct to clinical evaluation, increasing physician confidence and enabling more timely and appropriate therapeutic interventions.[5]

Ioflupane I-123: Identification and Physicochemical Profile

The precise characterization of a pharmaceutical agent is fundamental to its scientific understanding and clinical application. Ioflupane I-123 is identified by a comprehensive set of chemical, regulatory, and database identifiers that ensure its unambiguous recognition across scientific and clinical domains.

Nomenclature and Synonyms

The agent is known globally by several names and abbreviations. Its International Nonproprietary Name (INN) is Ioflupane (123I), while its United States Adopted Name (USAN) is Ioflupane I 123.[2] The formal chemical name, which describes its intricate molecular structure, is N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-123I-iodophenyl)nortropane, often expressed systematically as methyl (1R,2S,3S,5S)-8-(3-fluoropropyl)-3-(4-[123I]iodophenyl)-8-azabicyclo[3.2.1]octane-2-carboxylate.[3] In scientific literature, it is frequently referred to by the abbreviation 123I-FP-CIT.[3] Structurally, it is an azabicycloalkane and a phenyltropane compound, classified as a cocaine analogue due to its shared tropane backbone and its functional relationship to ecgonine, the foundational molecule from which cocaine is derived.[2]

Identifiers and Classification

Ioflupane I-123 is cataloged in major drug databases and regulatory systems. Its DrugBank ID is DB08824, and its Chemical Abstracts Service (CAS) Registry Number is 155798-07-5.[4] Under the Anatomical Therapeutic Chemical (ATC) classification system, it is assigned the code V09AB03, placing it in the category of diagnostic radiopharmaceuticals for the central nervous system involving Iodine-123 compounds.[15] It is classified as a small molecule, a radioactive diagnostic agent, and a radiopharmaceutical.[4]

Physicochemical and Radiopharmaceutical Properties

The injectable formulation of Ioflupane I-123 is a sterile, clear, colorless to faintly yellow aqueous solution with a faint alcoholic odor.[2] The solution is formulated for intravenous administration and, in addition to the active Ioflupane (I-123) and trace amounts of non-radioactive Ioflupane (I-127), contains several excipients: water for injection, ethanol (approximately 5%) to aid solubility, sodium acetate, and acetic acid to act as a buffer.[2]

The radiopharmaceutical properties of Ioflupane I-123 are defined by the Iodine-123 radionuclide. Iodine-123 has a physical half-life of 13.2 hours and decays by electron capture, emitting gamma radiation with a principal photon energy of 159 keV.[4] This energy level and half-life are ideal for medical imaging with standard SPECT gamma cameras, providing a strong signal for high-quality image acquisition while minimizing the patient's radiation exposure period.[2] A summary of these key properties is presented in Table 1.

Table 1: Physicochemical and Radiopharmaceutical Properties of Ioflupane I-123

Property	Value	Source(s)
International Nonproprietary Name (INN)	Ioflupane (123I)	2
United States Adopted Name (USAN)	Ioflupane I 123	11
Chemical Name	N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-123I-iodophenyl)nortropane	3
DrugBank ID	DB08824	4
CAS Registry Number	155798-07-5	11
ATC Code	V09AB03	15
Chemical Formula	C18​H23​F[123I]NO2​	11
Molecular Weight	Approx. 427.3 g/mol	11
Radionuclide	Iodine-123 (123I)	2
Physical Half-Life of 123I	13.2 hours	4
Principal Photon Energy	159 keV	2
Formulation Excipients	Water, Ethanol (5%), Sodium Acetate, Acetic Acid	2

Core Pharmacology and Mechanism of Action

The diagnostic utility of Ioflupane I-123 is intrinsically linked to its precise interaction with a specific component of the brain's neurochemistry—the nigrostriatal dopaminergic system. Its mechanism of action is a sophisticated example of molecular imaging, where a targeted radiolabeled molecule provides a functional snapshot of a physiological process.

The Nigrostriatal Dopaminergic System and Parkinsonian Syndromes

The brain contains several dopamine pathways, with the nigrostriatal pathway being the largest and most critical for motor control.[5] This pathway consists of dopaminergic neurons that originate in the substantia nigra pars compacta, a structure in the midbrain, and project to the striatum, a key component of the basal ganglia comprising the caudate nucleus and the putamen.[5] The dopamine released by these neurons in the striatum is essential for coordinating smooth, purposeful movement.

Parkinsonian Syndromes (PS) are a class of neurodegenerative disorders fundamentally characterized by the progressive loss of these dopaminergic neurons.[5] As these neurons degenerate, the production and availability of dopamine in the striatum decline significantly. This neurochemical deficit disrupts the normal functioning of the basal ganglia, leading to the cardinal motor symptoms of parkinsonism: resting tremor, bradykinesia (slowness of movement), rigidity, and postural instability.[5]

The Dopamine Transporter (DAT) as a Biomarker

Located on the presynaptic membrane of dopaminergic nerve terminals is a transmembrane protein known as the dopamine transporter, or DAT.[3] The primary function of DAT is to actively transport dopamine from the synaptic cleft back into the presynaptic neuron for reuse or degradation, a process called reuptake.[3] This action is crucial for terminating the dopaminergic signal and maintaining synaptic homeostasis.

The density of DATs on the surface of dopaminergic neurons is directly proportional to the number of viable, functional nerve terminals. Consequently, the progressive loss of neurons in the nigrostriatal pathway, which is the pathological hallmark of PS, leads to a corresponding and measurable reduction in the density of striatal DATs.[2] This makes DAT an excellent in-vivo biomarker for the integrity of the nigrostriatal dopaminergic system. Visualizing and quantifying the concentration of DATs provides a direct window into the underlying disease process.[22]

Molecular Mechanism of Ioflupane I-123

Ioflupane I-123 is engineered to exploit the role of DAT as a biomarker. As a structural analogue of cocaine, its molecular shape allows it to bind with high affinity and selectivity to the presynaptic dopamine transporter.[2] This binding action is reversible and positions the ioflupane molecule as a modulator at the transporter site.[4] The design of the ioflupane molecule represents a clever repurposing of a known chemical scaffold. While cocaine binds to DAT to block dopamine reuptake and produce a powerful psychoactive effect, ioflupane binds to the same target for an entirely different purpose. It does not exert a pharmacological effect at the diagnostic dose; instead, it serves as a highly specific delivery vehicle.

The key to its diagnostic function is the radioactive Iodine-123 isotope covalently bonded to the ioflupane molecule. This isotope acts as a reporter tag. Following intravenous injection, Ioflupane I-123 circulates through the bloodstream, crosses the blood-brain barrier, and accumulates in the striatum by binding to the dense population of DATs located there. The Iodine-123 atom then undergoes radioactive decay, emitting a 159 keV gamma photon.[2] These photons are able to pass through the brain and skull to be detected externally by a specialized gamma camera, which performs SPECT imaging. The SPECT system reconstructs the detected signals into a three-dimensional image that maps the distribution and density of the radiotracer—and by extension, the dopamine transporters—within the striatum.[2]

This process distinguishes Ioflupane I-123 SPECT as a functional molecular imaging technique, in contrast to anatomical imaging modalities like MRI or CT. An MRI scan can reveal the brain's structure, such as atrophy, but a DaTscan reveals the functional status of a specific neurotransmitter system. This is a critical distinction because the loss of DAT function, reflecting neuronal degeneration, often precedes the gross anatomical changes that might become visible on structural scans. Therefore, a normal DaTscan in a patient presenting with tremor provides powerful evidence that the underlying dopaminergic machinery is intact, a conclusion that strongly points away from a diagnosis of PS and cannot be reached with structural imaging alone. While its primary target is DAT, research has shown that Ioflupane I-123 also possesses some affinity for the serotonin transporter (SERT), which could potentially offer additional diagnostic information for differentiating among PS subtypes, though this application remains investigational.[23]

Pharmacokinetic and Pharmacodynamic Profile

The clinical utility and safety of Ioflupane I-123 are governed by its pharmacokinetic properties—how the body processes the drug—and its pharmacodynamic effects, including the radiation dose delivered to the patient.

Pharmacodynamics

The principal pharmacodynamic effect of Ioflupane I-123 is its high-affinity binding to dopamine transporters in the striatum.[2] Following intravenous administration, the concentration of the radiotracer in the striatum gradually increases as it is cleared from the blood and binds to its target. Peak striatal uptake relative to background brain tissue occurs between 3 and 6 hours after injection.[1] This specific time window is critical, as it represents the point of optimal signal-to-noise ratio for imaging, and thus defines the protocol for when SPECT scans should be performed. In individuals with a healthy dopaminergic system, approximately 30% of the total radioactivity that enters the brain becomes localized within the striatum.[4]

Pharmacokinetics

Absorption and Distribution: As Ioflupane I-123 is administered directly into the venous circulation, its absorption is instantaneous and its bioavailability is 100%.[4] Following injection, the radiotracer is rapidly distributed throughout the body and undergoes swift clearance from the bloodstream. This rapid blood clearance is essential for minimizing background signal during imaging. In healthy volunteers, the percentage of the injected radioactive dose remaining in whole blood decreases sharply in the first hour and more gradually thereafter [2]:

• At 5 minutes post-injection, radioactivity is 4.5% of the injected amount.
• At 30 minutes, this falls to 2.2%.
• At 5 hours, it is 1.9%.
• By 48 hours, only 1.1% of the initial radioactivity remains in the blood.

Metabolism: The specific metabolic pathways of Ioflupane I-123 have not been fully elucidated in the provided documentation.[4]

Excretion: The elimination of Ioflupane I-123 and its metabolites occurs through both renal and fecal routes. Over a 48-hour period, approximately 60% of the administered radioactive dose is excreted in the urine, with an additional 14% eliminated in the feces.[4] To facilitate this renal clearance and minimize the radiation dose to the bladder wall, patients are counseled to maintain good hydration and to void their bladder frequently for up to 48 hours following the procedure.[9]

Radiation Dosimetry

The administration of any radiopharmaceutical involves exposure to ionizing radiation. The risk associated with this exposure is quantified by the effective dose, a calculated measure that accounts for the absorbed dose to different organs and their relative sensitivities to radiation. For a standard administered activity of 185 MBq (5 mCi) of Ioflupane I-123, the effective dose to an adult patient is estimated to be between 3.94 mSv and 4.6 mSv.[1] This level of exposure is considered low and is comparable to that of other common nuclear medicine procedures. The organs that receive the highest absorbed radiation doses are typically those involved in excretion, such as the colon wall and the urinary bladder wall, as well as the uterus.[1] The key pharmacokinetic and dosimetry parameters are summarized in Table 2.

Table 2: Pharmacokinetic Parameters and Radiation Dosimetry of Ioflupane I-123

Parameter	Value	Source(s)
Route of Administration	Intravenous (IV) Injection	2
Bioavailability	100%	4
Optimal Imaging Window (Peak Striatal Uptake)	3 to 6 hours post-injection	1
Blood Radioactivity (% of injected dose)	4.5% at 5 min; 2.2% at 30 min; 1.9% at 5 hr; 1.1% at 48 hr	2
Route of Elimination (at 48 hours)	Approx. 60% in urine; 14% in feces	4
Radionuclide Half-Life (123I)	13.2 hours	4
Recommended Administered Activity	111 to 185 MBq (3 to 5 mCi)	1
Effective Dose (per 185 MBq)	3.94 - 4.6 mSv	1

Clinical Indications and Diagnostic Utility

Ioflupane I-123 SPECT imaging is not a standalone diagnostic test but rather a powerful adjunctive tool designed to provide objective biological data in specific, challenging clinical scenarios. Its approved indications address critical diagnostic crossroads in the evaluation of both movement disorders and dementia.

Primary Indication: Evaluation of Suspected Parkinsonian Syndromes

The foundational and most common indication for Ioflupane I-123 is for striatal dopamine transporter visualization to assist in the evaluation of adult patients with suspected Parkinsonian Syndromes (PS).[1] The primary clinical question it addresses is the differentiation of tremor due to PS from Essential Tremor (ET).[3] This is a frequent diagnostic dilemma, as both conditions can present with tremor, particularly in their early stages.

PS associated with presynaptic dopaminergic degeneration, such as Idiopathic Parkinson's Disease (PD), Multiple System Atrophy (MSA), and Progressive Supranuclear Palsy (PSP), are all characterized by a significant loss of nigrostriatal neurons and, consequently, a reduction in DAT density. A DaTscan in patients with these conditions will therefore be abnormal.[1] In contrast, conditions that can mimic the tremor of PS but do not involve this underlying pathology—such as ET, drug-induced parkinsonism, or psychogenic parkinsonism—are not associated with a loss of presynaptic dopaminergic neurons. A DaTscan in these patients will typically be normal.[3]

The diagnostic power of the scan is particularly evident when the result is normal. An abnormal scan confirms the presence of a striatal dopaminergic deficit, effectively "ruling in" a diagnosis within the broad category of PS. However, a normal scan in a patient with an uncertain tremor provides strong evidence to "rule out" a diagnosis of PD, MSA, or PSP. This negative result can dramatically alter the diagnostic and therapeutic pathway, preventing unnecessary trials of dopaminergic medications and reassuring the patient and clinician by pointing towards a diagnosis like ET. This capability is crucial given that clinical diagnosis of early-stage PS can be incorrect in up to 25% of cases, even when made by specialists.[5]

Expanded Indication: Evaluation of Suspected Dementia with Lewy Bodies

Reflecting a growing understanding of the overlapping pathologies of neurodegenerative diseases, the indication for Ioflupane I-123 has been expanded to include its use in the differential diagnosis of dementia. Specifically, it is indicated to help differentiate probable Dementia with Lewy Bodies (DLB) from Alzheimer's Disease (AD).[6]

This expansion acknowledges that the underlying biology of a disease, rather than just its initial clinical presentation, can be a more accurate basis for classification. DLB, like Parkinson's disease, is a synucleinopathy characterized by the presence of Lewy bodies and significant degeneration of the nigrostriatal dopaminergic pathway. As a result, patients with DLB will exhibit an abnormal DaTscan with reduced striatal uptake.[3] Alzheimer's disease, on the other hand, is a tauopathy, and while it may present with some motor symptoms, it is not typically associated with a primary loss of dopamine transporters. Therefore, patients with AD will generally have a normal DaTscan.[26] This distinction is of paramount clinical importance because patients with DLB are known to have severe, sometimes life-threatening, sensitivity to antipsychotic medications, which are often used to manage behavioral symptoms in dementia. An accurate diagnosis aided by DaTscan can help clinicians avoid these potentially harmful treatments and select more appropriate management strategies.[7]

Role as an Adjunctive Diagnostic Tool and Key Limitations

It is critical to recognize that Ioflupane I-123 SPECT is explicitly indicated as an adjunct to other diagnostic evaluations.[1] It is not intended to replace a thorough neurological examination and clinical history. Instead, it provides a piece of objective evidence about the integrity of a specific neurochemical system, which is then integrated into the overall clinical picture to arrive at a more confident diagnosis, particularly in cases of clinical uncertainty.[5]

Despite its strengths, the agent has important limitations. The most significant of these is its inability to differentiate among the various subtypes of Parkinsonian Syndromes. Because idiopathic PD, MSA, and PSP all involve presynaptic dopaminergic loss, they will all produce an abnormal DaTscan. The scan confirms a dopaminergic deficit but cannot, on its own, distinguish between these distinct clinical entities.[3] Furthermore, the effectiveness of Ioflupane I-123 for screening asymptomatic individuals, for confirming a clinically certain diagnosis, or for monitoring disease progression or a patient's response to therapy has not been established by regulatory bodies.[6]

Clinical Evidence and Pivotal Trials

The regulatory approval and widespread clinical adoption of Ioflupane I-123 are supported by a robust body of evidence from multiple clinical trials designed to assess its diagnostic accuracy and clinical impact.

Basis of Regulatory Approval

The initial approval by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) for the Parkinsonian Syndromes indication was based on data from several key studies, including two pivotal Phase 3 trials. These initial studies evaluated a total of 284 adult patients presenting with tremor, comparing the DaTscan results to a reference standard of expert clinical diagnosis.[10]

The most comprehensive evidence comes from a pooled analysis of four major clinical trials (three Phase 3 and one Phase 4) that were submitted as part of the U.S. new drug application. This analysis included data from 928 enrolled participants, with 764 completing the studies, providing a large and definitive dataset on the agent's performance.[8] The reference standard for diagnosis in these trials was not a simple baseline assessment but rather an expert clinical diagnosis made after a substantial follow-up period of 12 to 36 months, allowing for the natural evolution of symptoms to clarify the diagnosis over time.[8]

Diagnostic Performance Metrics

The pooled analysis evaluated the sensitivity and specificity of Ioflupane I-123 SPECT for detecting a striatal dopaminergic deficit disorder (SDDD), which includes both PS and DLB. The image interpretations were performed under two conditions: by on-site nuclear medicine physicians in a real-world setting and by a panel of independent expert readers who were blinded to all clinical information.

• Blinded Expert Reader Results: When images were assessed under controlled, blinded conditions, the diagnostic performance was exceptionally high. The overall sensitivity was 88.7% (95% Confidence Interval: 86.8% to 90.4%), and the overall specificity was 91.2% (95% CI: 89.0% to 93.0%).[8] These results demonstrate the agent's intrinsic ability to accurately distinguish between normal and abnormal dopaminergic systems.
• On-site Reader Results: The performance by on-site readers, reflecting typical clinical practice, also remained strong. The overall sensitivity was 91.9% (95% CI: 88.7% to 94.5%), and the overall specificity was 83.6% (95% CI: 78.7% to 87.9%).[8] The slight decrease in specificity in the on-site setting compared to the blinded read may reflect the influence of clinical information available to the readers.

Impact on Clinical Diagnosis and Management

Beyond demonstrating accuracy, clinical trials have also sought to answer the critical question of whether DaTscan imaging actually influences clinical practice. A key multi-center, randomized trial was conducted specifically in patients with clinically uncertain Parkinsonian syndromes (CUPS).[10] This study compared outcomes in a group of patients who underwent DaTscan imaging to a control group that did not.

The results showed that access to the DaTscan findings had a significant impact on clinical diagnosis. At the one-year follow-up, a substantial percentage of patients in the imaging group had their initial diagnosis changed based on the scan result. The study also found that the scan significantly increased physicians' confidence in their diagnoses, which in turn led to more informed and confident decisions regarding patient management and treatment.[10] Notably, the diagnostic impact was even more pronounced for general neurologists than for specialized movement disorder experts, highlighting the test's value in non-specialist settings where diagnostic uncertainty is often highest.[10] The evidence supporting the expanded indication for DLB was built upon studies demonstrating reduced striatal DAT binding in DLB patients compared to those with Alzheimer's Disease, with the pooled analysis also including dementia patients, thereby contributing to the data package submitted to the FDA for this indication.[7] A summary of this evidence is provided in Table 3.

Table 3: Summary of Pivotal Clinical Trial Evidence for Ioflupane I-123 SPECT Imaging

Analysis / Study	Patient Population	N (Completed)	Key Objective	Diagnostic Performance (Sensitivity / Specificity with 95% CI)	Key Finding/Conclusion	Source(s)
Pooled Analysis (4 Trials)	Movement disorders, dementia, healthy volunteers	764	Assess overall diagnostic accuracy for SDDD	Sensitivity: 88.7% (86.8% - 90.4%) Specificity: 91.2% (89.0% - 93.0%)	Visual assessment by blinded experts provides high sensitivity and specificity for detecting dopaminergic deficits.	8
Blinded Expert Read
Pooled Analysis (4 Trials)	Movement disorders, dementia, healthy volunteers	764	Assess overall diagnostic accuracy for SDDD	Sensitivity: 91.9% (88.7% - 94.5%) Specificity: 83.6% (78.7% - 87.9%)	On-site (unblinded) assessment also demonstrates high diagnostic effectiveness in a setting closer to clinical practice.	8
On-site Read
CUPS Impact Study	Patients with Clinically Uncertain Parkinsonian Syndromes (CUPS)	273	Evaluate the impact of DaTscan imaging on diagnosis and management	Not applicable (impact study)	DaTscan imaging significantly changed clinical diagnoses at 1 year and increased physician confidence, especially among general neurologists.	10
Pivotal Phase 3 Trials (2)	Adult patients with tremor (suspected PS vs. ET)	284	Confirm safety and efficacy for DAT visualization	Positive and negative percent agreements were high (e.g., 93% positive agreement in established diagnoses)	Demonstrated consistent performance in detecting DAT distribution compared to a reference clinical diagnosis, forming the basis for initial FDA approval.	10

Protocols for Administration and Imaging

The safe and effective use of Ioflupane I-123 is critically dependent on strict adherence to a standardized protocol that covers patient preparation, drug administration, and image acquisition. Deviations from this protocol can compromise not only the diagnostic quality of the scan but also patient safety.

Patient Preparation: The Imperative of Thyroid Blockade

A crucial and mandatory step in patient preparation is the blockade of the thyroid gland. The rationale for this procedure stems from the chemistry of the radiopharmaceutical. During its synthesis and shelf-life, a small fraction of the Iodine-123 can become detached from the ioflupane molecule, resulting in the presence of free radioiodide (up to 6%) in the injectable solution.[1] The thyroid gland has a powerful biological pump that actively concentrates iodide from the bloodstream to synthesize thyroid hormones. If not blocked, the gland will accumulate this free

123I, leading to unnecessary radiation exposure and, more significantly, a long-term increased risk for the development of thyroid neoplasia.[1]

To prevent this, a thyroid-blocking agent must be administered to the patient at least one hour prior to the injection of Ioflupane I-123.[1] These agents work by saturating the thyroid's iodide uptake mechanism with a large dose of non-radioactive iodine, effectively preventing the gland from taking up the radioactive

123I. Standard agents include Potassium Iodide Oral Solution or Lugol's Solution (providing a dose equivalent to 100 mg of stable iodide) or, alternatively, 400 mg of potassium perchlorate.[1]

Dosage and Administration

The recommended dose of Ioflupane I-123 for an adult patient is a single intravenous injection with an activity ranging from 111 to 185 Megabecquerels (MBq), which is equivalent to 3 to 5 millicuries (mCi).[1] It is essential that the exact activity of the patient's dose is measured in a suitable radioactivity calibration system (a dose calibrator) immediately before it is administered to ensure accuracy.[1] The injection should be administered slowly into a peripheral vein, typically over a period of at least 15 to 20 seconds.[31]

Imaging Protocol

The timing of the SPECT scan is dictated by the pharmacokinetics of the radiotracer. As established, the optimal signal-to-noise ratio, with maximal tracer accumulation in the striatum and sufficient clearance from surrounding background tissues, occurs between 3 and 6 hours after the injection.[1] Therefore, SPECT imaging must be initiated within this specific window. The acquisition is performed using a standard dual-head SPECT gamma camera equipped with appropriate collimators for the 159 keV energy of Iodine-123.

The rigorous nature of this protocol highlights that the success of a DaTscan is a function of both the radiopharmaceutical's properties and the fidelity of the procedure. A failure at any step, from neglecting the thyroid blockade to incorrect scan timing, can invalidate the results or introduce unnecessary risk. This underscores the critical importance of quality control and standardized procedures within the nuclear medicine department.

Post-Administration Patient Instructions

Following the injection, patients should be advised to maintain adequate hydration by drinking plenty of fluids. They should also be encouraged to urinate as frequently as possible for at least the first 48 hours.[24] This practice helps to accelerate the renal clearance of any unbound radiotracer and its metabolites, thereby minimizing the radiation dose absorbed by the urinary bladder and the body as a whole.[9]

Interpretation of SPECT Imaging Results

The interpretation of Ioflupane I-123 SPECT images involves a systematic visual assessment of the pattern and intensity of radiotracer uptake in the striatum. The distinct visual patterns observed on the scan correlate directly with the health of the nigrostriatal dopaminergic system.

Qualitative (Visual) Assessment

The primary method of interpretation, and the one approved by the FDA, is a qualitative visual assessment of the reconstructed SPECT images.[19]

• Normal Scan: In a healthy individual, the scan reveals two intense, symmetric, comma-shaped areas of high radioactivity corresponding to the left and right striata. The "head" of the comma, which is brighter and more rounded, represents the caudate nucleus, while the "tail," which is less intense and tapers posteriorly, represents the putamen. This distinct comma shape should be clearly visible against the low, diffuse background activity of the surrounding brain tissue.[5] A normal scan signifies an intact presynaptic dopaminergic system.
• Abnormal Scan: An abnormal scan is defined by the reduced or absent uptake of the radiotracer in the striatum, particularly in the putamen. The loss of signal is often asymmetric, being more pronounced on one side than the other, which correlates with the typically asymmetric onset of motor symptoms in Parkinson's disease.[1] The progression of these visual changes often follows a characteristic pattern:
• Early-Stage Disease: The earliest detectable abnormality is typically a loss of signal in the posterior putamen. This loss of the "tail" of the comma results in a truncated shape, often described as an "oval" or, in more advanced cases, a "period" or "circular" shape, where only the caudate head retains significant activity.[5]
• Progressive Disease: As the neurodegenerative process continues, the loss of radiotracer uptake extends from the posterior to the anterior putamen and, in later stages, involves the caudate nucleus as well.[5]

This descriptive terminology of "comma to period" is more than just convenient jargon; it serves as a powerful visual narrative of the disease process. The shape seen on the scan is a direct representation of the known pathophysiology of Parkinson's disease, where the neurodegenerative process typically affects the putamen more severely and earlier than the caudate nucleus. The radiologist or nuclear medicine physician is, in essence, visualizing the anatomical progression of the disease within the striatum in a single functional image.

Pathophysiological Correlation and Semi-Quantitative Analysis

It is important to note that by the time a patient develops motor symptoms sufficient to warrant a DaTscan, the underlying neuronal loss is already substantial. Pathological studies have shown that 50-60% of dopaminergic neurons in the substantia nigra may be lost before the classic motor signs of Parkinson's disease become clinically apparent.[5] For this reason, the imaging findings in a positive scan are generally not subtle.

While visual assessment is the standard, it can be supplemented by semi-quantitative analysis.[3] These methods use software to place regions of interest (ROIs) over the striatum (caudate and putamen) and a reference region, such as the occipital cortex, which has negligible DAT density. The software then calculates a striatal binding ratio, providing an objective numerical value for radiotracer uptake that can be compared to a database of normal values.[13] This can be particularly helpful in equivocal cases or for research purposes.

Comprehensive Safety and Tolerability Profile

Ioflupane I-123 is generally well-tolerated, with a safety profile established through extensive clinical trials and over two decades of post-marketing experience. However, as with any medical procedure involving an injectable agent and ionizing radiation, there are specific risks, warnings, and contraindications that must be understood.

Adverse Reactions

The incidence of adverse reactions associated with Ioflupane I-123 is low.

• Clinical Trial Experience: In controlled clinical trials, adverse events were reported in less than 1% of subjects. These reactions were consistently of mild to moderate severity and were transient in nature.[1] The most frequently reported events include:
• Headache [2]
• Nausea [24]
• Vertigo, dizziness, or a sensation of spinning [2]
• Dry mouth [24]
• Less commonly, increased appetite and formication (a tingling or crawling sensation on the skin) have been noted.[2]
• Post-marketing Experience: In the broader patient population, post-marketing surveillance has identified hypersensitivity reactions and injection site pain or other local reactions (e.g., redness, swelling) as additional potential adverse events.[1]

Contraindications

There are two absolute contraindications for the use of Ioflupane I-123:

1. Known Hypersensitivity: The agent must not be administered to patients with a known history of hypersensitivity to ioflupane, to any of the excipients in the formulation (such as ethanol or sodium acetate), or to iodine.[3]
2. Pregnancy: Due to the potential risk of radiation exposure to the developing fetus, the use of Ioflupane I-123 is contraindicated in pregnant women.[2]

Warnings and Precautions

• Hypersensitivity Reactions: As with any intravenously administered agent, there is a risk of hypersensitivity or anaphylactic reactions. Reported reactions have included symptoms such as dyspnea (difficulty breathing), edema (swelling), rash, erythema (skin redness), and pruritus (itching).[1] These reactions typically occur soon after administration. It is imperative that appropriate medical personnel and resuscitation equipment are readily available during and after the injection. Patients should be questioned about prior reactions before administration and monitored for signs of hypersensitivity afterward.[1]
• Thyroid Accumulation: This is a major safety warning. As previously detailed, failure to administer a thyroid-blocking agent at least one hour before the injection can lead to the accumulation of free 123I in the thyroid gland, which increases the long-term risk of thyroid neoplasia. This is a preventable risk, and adherence to the thyroid blockade protocol is mandatory.[1]

Use in Specific Populations

• Lactation: It is not known whether Ioflupane I-123 is excreted into human breast milk. To minimize the potential radiation exposure to a breastfeeding infant, nursing mothers should be advised to interrupt breastfeeding. The manufacturer recommends that the mother pump and discard her breast milk for at least 6 days following administration of the agent.[2]
• Pediatric Use: The safety and efficacy of Ioflupane I-123 have not been established in patients under 18 years of age, and it is not indicated for pediatric use.[1]
• Geriatric Use: Clinical studies have not shown any significant differences in safety or effectiveness between elderly and younger adult patients. No dose adjustment is required based on age.[1]
• Renal and Hepatic Impairment: The kidneys are a major route of excretion for Ioflupane I-123. In patients with severe renal impairment, the clearance of the radiotracer may be reduced, which could potentially lead to increased radiation exposure and may alter the quality of the SPECT image. Therefore, the agent should be used with caution in this population.[9] The effect of hepatic impairment on the pharmacokinetics of Ioflupane I-123 has not been established.

Overdosage

An overdose of Ioflupane I-123 is primarily a concern related to radiation exposure rather than pharmacological toxicity. The major risks are an increased total body radiation dose and a corresponding elevation in the long-term risk for radiation-induced neoplasia. In the event of an overdose of radioactivity, management should focus on accelerating the elimination of the radiotracer from the body. This is best achieved by encouraging frequent urination and defecation.[6] It is not known if ioflupane is removable by dialysis.[9]

Significant Drug and Disease Interactions

The diagnostic accuracy of an Ioflupane I-123 SPECT scan can be significantly affected by concomitant medications. A thorough review of a patient's medication list is a critical part of the pre-procedural preparation to avoid misinterpretation of the imaging results.

Mechanisms of Interaction

Drug interactions with Ioflupane I-123 can be broadly categorized into two types:

1. Pharmacodynamic Interactions: This is the most clinically significant category. It involves drugs that bind directly to the dopamine transporter (DAT). These medications act as competitive inhibitors, occupying the same binding sites that Ioflupane I-123 is designed to target. This competition reduces the amount of radiotracer that can bind in the striatum, leading to a falsely low signal on the SPECT image. Such an artifact could be misinterpreted as evidence of a dopaminergic deficit, potentially leading to a false-positive diagnosis of a Parkinsonian Syndrome.[6]
2. Pharmacokinetic Interactions: This category includes drugs that may alter the absorption, distribution, metabolism, or excretion of Ioflupane I-123. For instance, some medications may decrease the renal excretion rate, leading to higher serum levels of the radiotracer, while others may increase it, leading to lower levels. These effects could potentially impact image quality or the patient's overall radiation dose.[4]

Classes of Interfering Drugs

A wide range of centrally-acting medications can interfere with DaTscan imaging, primarily through pharmacodynamic competition at the DAT. Clinicians must be aware of these potential interactions and, in consultation with the referring physician and nuclear medicine team, decide whether these medications can be safely withheld for an appropriate period before the scan. A summary of key interacting drug classes is provided in Table 4.

Table 4: Clinically Significant Drug Interactions with Ioflupane I-123

Drug/Drug Class	Mechanism of Interaction	Potential Effect on DaTscan Image	Clinical Recommendation	Source(s)
CNS Stimulants (e.g., Amphetamine, Methylphenidate, Modafinil)	Competitive binding to DAT	Decreased striatal uptake, potentially causing a false-positive result.	Review medication necessity; consider temporary discontinuation based on clinical judgment and drug half-life.	30
Cocaine	High-affinity competitive binding to DAT	Markedly decreased striatal uptake, mimicking advanced PS.	Patient should not use cocaine prior to scan.	30
Certain Antidepressants (e.g., Bupropion, Sertraline, Citalopram, Amoxapine)	Competitive binding to DAT	Decreased striatal uptake, potentially causing a false-positive result.	Review medication; discontinuation may be necessary. The effect varies by agent (e.g., Bupropion is a strong interactor).	30
Anorectics (Appetite Suppressants) (e.g., Phentermine, Mazindol)	Competitive binding to DAT	Decreased striatal uptake, potentially causing a false-positive result.	Review medication necessity; consider temporary discontinuation.	30
Anticholinergics with DAT activity (e.g., Benztropine)	Competitive binding to DAT	Decreased striatal uptake, potentially causing a false-positive result.	Review medication; consider temporary discontinuation.	30
Dopaminergic Agents (e.g., Levodopa, Dopamine Agonists, Amantadine)	Unclear; may alter DAT expression or binding	The impact has not been definitively established, but interference is possible.	Most protocols do not require discontinuation, but this should be noted in the report.	6
Drugs Affecting Renal Excretion (e.g., Amiloride, Acetazolamide, many others)	Alteration of renal clearance	Increased or decreased serum levels of the radiotracer, potentially affecting image quality or radiation dose.	Generally not considered a contraindication, but awareness is important, especially in patients with renal impairment.	4

Disease State Interactions

In addition to drug interactions, certain patient conditions warrant special consideration:

• Severe Renal Impairment: As the kidneys are a primary route of elimination, patients with severe renal disease may have delayed clearance of the radiotracer. This could increase their overall radiation exposure and potentially degrade image quality due to higher background activity.[33]
• Thyroid Dysfunction: Patients with pre-existing thyroid disorders should be managed carefully. The thyroid blockade protocol remains essential, and the patient's endocrinologist may need to be consulted.[33]

Regulatory and Commercial Landscape

The journey of Ioflupane I-123 from a novel research compound to a globally recognized diagnostic standard is reflected in its regulatory history and commercial status.

Regulatory Approval History

A notable aspect of Ioflupane I-123's history is the significant time lag between its approval in Europe and the United States.

• European Medicines Agency (EMA): The agent was first granted marketing authorization throughout the European Union on July 27, 2000, under the brand name DaTSCAN. The authorization is held by GE Healthcare.[12] This early approval meant that by the time the agent was being considered by U.S. regulators, a vast repository of real-world, post-marketing safety and efficacy data from its use in hundreds of thousands of European patients was already available.[27]
• U.S. Food and Drug Administration (FDA): After an 11-year gap, the FDA approved the agent on January 14, 2011, under the brand name DaTscan (NDA 22-454).[27] The FDA granted the application a Priority Review, recognizing the unmet clinical need for an imaging agent to assist in the diagnosis of suspected Parkinsonian Syndromes.[28]
• Expanded FDA Indication: On November 3, 2022, the FDA approved an expanded indication for DaTscan, allowing its use to assist in the evaluation of adult patients with suspected Dementia with Lewy Bodies (DLB).[7]

Controlled Substance Classification

In the United States, Ioflupane I-123 is classified as a Schedule II controlled substance under the Controlled Substances Act.[27] This scheduling presents a unique regulatory situation. Schedule II is reserved for substances with a high potential for abuse that may lead to severe psychological or physical dependence. While Ioflupane I-123 is structurally a cocaine analogue (a tropane derivative), its final formulation as a highly dilute, radioactive injectable solution for diagnostic use presents no practical potential for abuse. The classification is based on the molecule's chemical lineage rather than its clinical function or risk profile. This creates a significant operational burden for hospitals and nuclear pharmacies, which must adhere to the strict storage, inventory, and record-keeping requirements for Schedule II substances, a regulatory artifact driven by chemical structure rather than pharmacological reality.

Commercial Landscape

• Originator Product: The original branded product is DaTscan, developed and marketed globally by GE Healthcare.[37]
• Generic Competition: The market for Ioflupane I-123 expanded in the United States in March 2022 with the FDA approval of a generic version manufactured by Curium Pharma.[9] The introduction of generic competition can increase accessibility and may influence pricing. Under FDA regulations, generic products are required to have the same labeling as the reference listed drug, meaning that as new indications are approved for DaTscan, they are also adopted for the generic versions.[6]
• Other Brand Names: In Europe, another brand name for a generic version is Striascan.[31]

Expert Analysis and Future Directions

Ioflupane I-123 SPECT has established itself as a cornerstone of modern diagnostic neurology and nuclear medicine. Its introduction has fundamentally altered the diagnostic paradigm for patients with uncertain parkinsonism and related dementias, shifting the field away from purely clinical and often uncertain diagnoses toward a more objective, biologically-based approach.

Synthesis of Impact on Diagnostic Paradigms

Before the availability of DAT imaging, the differential diagnosis of early-stage tremor disorders was fraught with uncertainty, leading to high rates of misdiagnosis.[5] Ioflupane I-123 provided the first widely available tool to visualize the underlying pathophysiology of Parkinsonian Syndromes in vivo. By offering objective evidence of the integrity of the nigrostriatal dopaminergic system, it has empowered clinicians to make more accurate and timely diagnoses. This has had a profound impact on patient management, allowing for the earlier initiation of appropriate therapies in patients with PS and, just as importantly, avoiding unnecessary and potentially harmful treatments in patients with non-dopaminergic conditions like Essential Tremor.[10] The increase in diagnostic confidence among physicians, particularly non-specialists, is a testament to its clinical value.[10]

Current Research and Emerging Applications

While its clinical role is well-defined, Ioflupane I-123 continues to be a valuable tool in clinical research, helping to advance the understanding of neurodegenerative diseases. It is currently being used in clinical trials as a biomarker to stratify patient cohorts, such as in studies investigating the specific neurobiological features of Parkinson's disease associated with genetic mutations like LRRK2 or GBA.[40] It is also being employed to explore the relationship between different neurotransmitter systems; for example, by correlating DAT imaging with tracers for the cholinergic system to better understand the complex neurochemistry of DLB.[41] Furthermore, there is significant research interest in its use to identify individuals in the prodromal phase of disease. Studies in patients with conditions like REM Sleep Behavior Disorder (RBD), who are at very high risk of developing a synucleinopathy like PD or DLB, use DaTscan to detect presymptomatic dopaminergic deficits, opening a potential window for future disease-modifying interventions.[20]

Future Directions and Unanswered Questions

Despite its success, several key questions and future directions remain for Ioflupane I-123 and DAT imaging.

1. Overcoming the Primary Limitation: A major focus of ongoing research is to determine if advanced image analysis techniques, moving beyond simple visual or semi-quantitative assessment, can unlock the potential for DAT imaging to differentiate among the PS subtypes. Subtle differences in the pattern or asymmetry of DAT loss between PD, MSA, and PSP may exist, and sophisticated analytical methods could potentially extract this diagnostically valuable information.[23]
2. Role in Monitoring and Therapeutic Trials: Although not currently an approved indication, the potential for Ioflupane I-123 to serve as a biomarker for monitoring disease progression or measuring the efficacy of novel, disease-modifying therapies is an area of intense investigation. If validated for this purpose, it could become an essential tool in the development of next-generation treatments for Parkinson's disease.[9]
3. Positioning Among Emerging Biomarkers: The field of neurodegenerative disease diagnostics is rapidly evolving with the development of new biomarkers, including advanced PET tracers, cerebrospinal fluid (CSF) assays like the α-synuclein seed amplification assay, and promising blood-based markers. The future diagnostic algorithm will likely involve a multi-modal approach, and a key challenge will be to define the optimal role and sequence of DAT imaging in relation to these other powerful diagnostic tools.

In conclusion, Ioflupane I-123 is a mature and highly effective diagnostic radiopharmaceutical that has rightfully earned its place as a standard of care in the evaluation of clinically challenging cases of suspected Parkinsonian Syndromes and Dementia with Lewy Bodies. It has resolved diagnostic uncertainty for countless patients, guided more appropriate clinical management, and continues to serve as a vital platform for research aimed at unraveling the complex biology of neurodegenerative disease.

Works cited

1. Ioflupane I 123 Injection, Solution | Curium Pharma, accessed August 28, 2025, https://www.curiumpharma.com/wp-content/uploads/2022/03/Ioflupane-PI_R122021.2.pdf
2. Ioflupane (123I) - Wikipedia, accessed August 28, 2025, https://en.wikipedia.org/wiki/Ioflupane_(123I)
3. SNM Practice Guideline for Dopamine Transporter Imaging with 123 I-Ioflupane SPECT 1.0, accessed August 28, 2025, https://jnm.snmjournals.org/content/53/1/154
4. Ioflupane I-123: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 28, 2025, https://go.drugbank.com/drugs/DB08824
5. Practical Overview of 123 I-Ioflupane Imaging in Parkinsonian Syndromes - RSNA Journals, accessed August 28, 2025, https://pubs.rsna.org/doi/full/10.1148/rg.230133
6. Curium Announces New Indication for Ioflupane I 123 Injection in the U.S., accessed August 28, 2025, https://www.curiumpharma.com/2022/11/22/new-indication-ioflupane/
7. DATSCAN™ (Ioflupane I 123 Injection) indication expanded to include use in patients with suspected Dementia with Lewy Bodies (DLB) - Business Wire, accessed August 28, 2025, https://www.businesswire.com/news/home/20221103005731/en/DATSCAN-Ioflupane-I-123-Injection-indication-expanded-to-include-use-in-patients-with-suspected-Dementia-with-Lewy-Bodies-DLB
8. Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials - PMC, accessed August 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4091455/
9. Curium Announces FDA Approval of a Generic Version of DaTscan™ (Ioflupane I 123 Injection) in the U.S., accessed August 28, 2025, https://www.curiumpharma.com/2022/04/05/curium-announces-fda-approval-of-a-generic-version-of-datscan-ioflupane-i-123-injection-in-the-u-s/
10. DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging Demonstrates Impact on the Diagnosis and Clinical Management of Patients with Clinically Uncertain Parkinsonian Syndrome - GE Healthcare, accessed August 28, 2025, https://www.gehealthcare.com/about/newsroom/press-releases/datscan%E2%84%A2-ioflupane-i-123-injection-spect-imaging-demonstrates-impact-diagnosis-and
11. IOFLUPANE I 123, accessed August 28, 2025, https://searchusan.ama-assn.org/usan/documentDownload?uri=/unstructured/binary/usan/ioflupane-i-123.pdf
12. Ioflupane I-123 | C18H23FINO2 | CID 3086674 - PubChem, accessed August 28, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Ioflupane-I-123
13. CHEBI:68855 - ioflupane I 123 - EMBL-EBI, accessed August 28, 2025, https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:68855
14. Ioflupane I 123 | CAS#155798-07-5 - MedKoo Biosciences, accessed August 28, 2025, https://www.medkoo.com/products/28963
15. Ioflupane I 123 - brand name list from Drugs.com, accessed August 28, 2025, https://www.drugs.com/ingredient/ioflupane-i-123.html
16. KEGG DRUG: Ioflupane I 123, accessed August 28, 2025, https://www.genome.jp/dbget-bin/www_bget?drug:D10014
17. SDS US - Curium Pharma, accessed August 28, 2025, https://www.curiumpharma.com/wp-content/uploads/2020/08/SDS-US-Ioflupane-I-123-injection-final.pdf
18. Ioflupane I 123 - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf, accessed August 28, 2025, https://www.ncbi.nlm.nih.gov/books/NBK501915/
19. Practical Overview of 123I-Ioflupane Imaging in Parkinsonian Syndromes - PubMed, accessed August 28, 2025, https://pubmed.ncbi.nlm.nih.gov/38236751/
20. Study Details | DaTSCAN Imaging in Aging and Neurodegenerative Disease, accessed August 28, 2025, https://clinicaltrials.gov/study/NCT01453127
21. Practical Overview of 123I-Ioflupane Imaging in Parkinsonian Syndromes - Geisel School of Medicine, accessed August 28, 2025, https://geiselmed.dartmouth.edu/radiology/wp-content/uploads/sites/47/2024/03/Practical-overview-of-ioflupane-imaging.pdf
22. Optimizing the Diagnosis of Parkinsonian Syndromes With 123I-Ioflupane Brain SPECT | AJR - American Journal of Roentgenology, accessed August 28, 2025, https://ajronline.org/doi/10.2214/AJR.19.21088
23. Ioflupane-I-123 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed August 28, 2025, https://synapse.patsnap.com/drug/12e06c32d1e64015bfb255d2234e9eb3
24. Ioflupane i 123 (intravenous route) - Side effects & uses - Mayo Clinic, accessed August 28, 2025, https://www.mayoclinic.org/drugs-supplements/ioflupane-i-123-intravenous-route/description/drg-20074736
25. DaTscan (Ioflupane I 123 Injection) for Intravenous Use, CII - accessdata.fda.gov, accessed August 28, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022454Orig1s000Lbl.pdf
26. The role of 123I-ioflupane SPECT dopamine transporter imaging in the diagnosis and treatment of patients with dementia with Lewy bodies - PMC, accessed August 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2654798/
27. FDA Approves DaTscan for Imaging of Dopamine Transporters - Medscape, accessed August 28, 2025, https://www.medscape.com/viewarticle/735875
28. FDA APPROVES DaTscan™ (Ioflupane I 123 Injection) FOR VISUALIZATION OF DOPAMINE TRANSPORTERS IN PATIENTS WITH SUSPECTED PARKINSONIAN SYNDROMES | GE HealthCare (United States), accessed August 28, 2025, https://www.gehealthcare.com/about/newsroom/press-releases/fda-approves-datscan%E2%84%A2-ioflupane-i-123-injection-visualization-dopamine-transporters
29. Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials - ResearchGate, accessed August 28, 2025, https://www.researchgate.net/publication/263707827_Is_ioflupane_I123_injection_diagnostically_effective_in_patients_with_movement_disorders_and_dementia_Pooled_analysis_of_four_clinical_trials
30. DaTscan™ - accessdata.fda.gov, accessed August 28, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022454Orig1s004lbl.pdf
31. Striascan | European Medicines Agency (EMA), accessed August 28, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/striascan
32. DaTscan (ioflupane I123) dosing, indications, interactions, adverse effects, and more, accessed August 28, 2025, https://reference.medscape.com/drug/datscan-ioflupane-i-123-999618
33. Ioflupane I 123 Interactions - Drugs.com, accessed August 28, 2025, https://www.drugs.com/drug-interactions/ioflupane-i-123.html
34. Patient preparation: Potential Drug Interference with DaTSCAN - GE HealthCare, accessed August 28, 2025, https://www.gehealthcare.co.uk/-/media/global/products/files/nuclear-imaging-agents/datscan/jb01186uk-datscan-drug-interaction-summary-digital-2.pdf?rev=-1
35. DaTscan Interactions Checker - Drugs.com, accessed August 28, 2025, https://www.drugs.com/drug-interactions/ioflupane-i-123,datscan.html
36. DaTSCAN | European Medicines Agency (EMA), accessed August 28, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/datscan
37. DaTscan (ioflupane I 123) FDA Approval History - Drugs.com, accessed August 28, 2025, https://www.drugs.com/history/datscan.html
38. 022454Orig1s000 - accessdata.fda.gov, accessed August 28, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022454sOrig1s000OtherR.pdf
39. DaTSCAN™ (Ioflupane I 123 Injection) Now Available to Help Physicians Assess Patients with Suspected Parkinsonian Syndromes - GE Healthcare, accessed August 28, 2025, https://www.gehealthcare.com/about/newsroom/press-releases/datscan%E2%84%A2-ioflupane-i-123-injection-now-available-help-physicians-assess-patients
40. Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients With Different Genetic Characteristics | ClinicalTrials.gov, accessed August 28, 2025, https://clinicaltrials.gov/study/NCT01089283
41. The Practice of DaTscan Ioflupane I-123 Proposes New Opportunities to Diagnose Lewy Body Dementia Diseases in Clinical Trial Setting | Journal of Nuclear Medicine, accessed August 28, 2025, https://jnm.snmjournals.org/content/56/supplement_3/2711